Selvita is a pre-clinical CRO and drug discovery company founded in 2007 in Krakow, Poland. We offer support for drug discovery development at every stage of the early discovery phase up to the preclinical research.
The company was established in 2007 and currently employs over 360 scientists, among which 30% are PhDs.
Selvita's laboratories are located in Krakow, Poland and possess both GLP and GMP certification. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe.
Selvita offers integrated drug discovery projects helping biotech and pharma partners discover and develop new drugs. Our scientists have an extensive experience in several areas of life sciences, and we offer the following types of projects:
- Contract chemistry services: medicinal chemistry, custom organic synthesis, scale-up and process chemistry, as well as industrial chemistry
- Biology services: cell and molecular biology, ADME and pharmacokinetics, proteomic analyses, analytical chemistry and method validation
- Integrated drug discovery projects combining variety of drug discovery processes from in silico drug design, and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro development, all tailored to the customer’s needs
- Comparative studies of biosimilar medicinal products, including a wide range of analytical services, as well as molecular biology and biochemistry assays, successfully applied in biosimilar drug development.
Selvita specializes in a broad spectrum of pharmacodynnamic in vitro studies used to analyze biosimilar product's activity in comparison to adequate reference compounds. We offer assays that are able to detect even minor changes in biological response to pharmacologically active substances.
Company offices are located in Cambridge, MA, San Francisco Bay Area in the USA as well as Krakow, Poland and Cambridge, UK.
Selvita also develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Currently company has focused its research and development efforts in the area of oncology.
